CAJ | 학술논문

目的：探讨替吉奥胶囊联合注射用奥沙利铂（ SOX方案）在进展期胃癌中应用的有效性和安全性。方法选取76例进展期胃癌患者为研究对象，随机分为观察组和对照组各38例。观察组采用口服替吉奥胶囊80 mg/（ m2· d）2次/d，第1～14天；奥沙利铂130 mg/（ m2· d），第1天，静脉滴注，3周为1个疗程。对照组采用奥沙利铂130 mg/（ m2· d），第1天，静脉滴注；口服卡倍他滨2000 mg/（ m2· d），2次/d，第1～14天，3周为1个疗程。治疗2个疗程后比较2组患者的临床疗效、生活质量及不良反应情况。结果观察组患者治疗后的总有效率和临床获益率分别为68．4％和92．1％，对照组分别为55．3％和76．3％，2组比较，差异有统计学意义（P＜0．05）；观察组患者治疗后生存质量（KPS评分）优于对照组，差异具有统计学意义（P＜0．05）；2组患者的不良反应主要为血液学毒性、胃肠道反应等，以Ⅰ～Ⅱ度为主，观察组患者白细胞计数下降率、恶心呕吐发生率、腹泻发生率分别为39．5％、42．1％、10．5％，显著低于对照组的65．8％、89．5％、36．8％，均具有统计学意义（P＜0．05），其他不良反应则无统计学意义（P＞0．05）。结论替吉奥联合奥沙利铂治疗进展期胃癌具有较高的有效性，不良反应率较低，可明显改善患者的生存质量，值得在临床推广应用。
목적：탐토체길오효낭연합주사용오사리박（ SOX방안）재진전기위암중응용적유효성화안전성。방법선취76례진전기위암환자위연구대상，수궤분위관찰조화대조조각38례。관찰조채용구복체길오효낭80 mg/（ m2· d）2차/d，제1～14천；오사리박130 mg/（ m2· d），제1천，정맥적주，3주위1개료정。대조조채용오사리박130 mg/（ m2· d），제1천，정맥적주；구복잡배타빈2000 mg/（ m2· d），2차/d，제1～14천，3주위1개료정。치료2개료정후비교2조환자적림상료효、생활질량급불량반응정황。결과관찰조환자치료후적총유효솔화림상획익솔분별위68．4％화92．1％，대조조분별위55．3％화76．3％，2조비교，차이유통계학의의（P＜0．05）；관찰조환자치료후생존질량（KPS평분）우우대조조，차이구유통계학의의（P＜0．05）；2조환자적불량반응주요위혈액학독성、위장도반응등，이Ⅰ～Ⅱ도위주，관찰조환자백세포계수하강솔、악심구토발생솔、복사발생솔분별위39．5％、42．1％、10．5％，현저저우대조조적65．8％、89．5％、36．8％，균구유통계학의의（P＜0．05），기타불량반응칙무통계학의의（P＞0．05）。결론체길오연합오사리박치료진전기위암구유교고적유효성，불량반응솔교저，가명현개선환자적생존질량，치득재림상추엄응용。
Objective To explore the efficacy and safety of S-1 combined with oxaliplatin injection ( SOX scheme ) for advanced gastric cancer .Methods 76 cases of advanced gastric cancer patients were randomly divided into the observation group and the control group ,with 38 cases in each group .The observation group received S-1 80 mg/( m2 · d) twice a day orally ,from 1 to 14 days,and oxaliplatin 130 mg/(m2· d) with intravenous drip on the first day,3 weeks was 1 cycle.The control group re-ceived oxaliplatin 130 mg/(m2· d) with intravenous drip on the first day and Capecitabine 2 000 mg/(m2· d) twice a day,from 1 to 14 days,3 weeks was 1 cycle.The clinical curative effect ,life quality and adverse reactions of the 2 groups after 2 courses of treatment were compared .Results The total effective rate and clinical benefit rate after treatment in the observation group were 68.4%and 92.1%respectively,while those of the control group were 55.3% and 76.3% respectively,there was a statistical difference (P<0.05) ;The quality of life (KPS score) after treatment in the observation group was better than that of the control group,there was a statistical difference (P<0.05);The adverse reactions of the 2 groups were mainly Ⅰ~Ⅱdegree hematologic toxicity,gastrointestinal reaction ,etc,the leukocyte count decline rate ,incidence of nausea and vomiting ,diarrhea incidence of the observation group were 39.5%,42.1%,10.5% respectively,which were significantly lower than those of the control group (65.8%,89.5%,36.8%),there was a statistical difference (P<0.05),while there was no statistical difference (P>0.05) in other adverse reactions .Conclusion S-1 combined with oxaliplatin for advanced gastric cancer has high efficiency ,lower adverse reaction rate ,it can obviously improve the patient's quality of life ,and it is worthy of clinical application .